Coramitug is well tolerated and leads to a statistically significant reduction in N-terminal pro-brain type natriuretic peptide (NT-proBNP)—a marker of disease progression in transthyretin-mediated ...

Important gains were observed in key areas, including basic theory, transfusion compatibility testing, and clinical transfusion application. A structured 6-month fellowship program in transfusion ...

While there is currently no cure, pharmacological therapies for progressive pulmonary fibrosis (PPF) include immunomodulatory agents that aim to reduce inflammation and antifibrotics that delay ...

Awareness of the key symptoms of NF1 can help in early diagnosis. A young male patient was diagnosed with neurofibromatosis type 1 (NF1) after undergoing detailed clinical investigations, according to ...

Ivabradine treatment slowed resting heart rate and reduced the levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) in some patients with ATTR. MINNEAPOLIS—The sodium channel ...

Emerging therapies such as bezuclastinib and elenestinib show promise in improving disease control with potentially fewer toxicities. Other novel strategies, such as immune-based therapies, are under ...

The majority (90%) of neurologists were aware of 40 out of 61 recommendations on the treatment of myasthenia gravis (MG). Most Spanish neurologists know, agree on, and apply guidelines for the ...

Intercept Pharmaceuticals, the developer of the PBC drug, suggested that the company's view on the drug's benefit and risk profile differed from that of the US Food and Drug Administration.

The potential of vitamin D as an add-on therapy lies in its immunomodulatory effect on T cell-mediated and humoral immune responses, complement activation, cytokines, and inflammasomes. Vitamin D ...

The visual acuity of patients with AQP4 antibody-positive NMOSD was significantly worse than that of patients with MOGAD. The visual and functional impairment in the eyes of patients with optic ...

A baseline bleeding risk of 7.3 bleeds per year was observed without any FIX, and targeting trough FIX levels between 10 and 20 IU/dL reduced bleeds to very low or eliminated them. In people with ...

Ruxolitinib exerts its activity independently of oncogenic Janus kinase 2 (JAK2)-V617F signaling in myeloproliferative neoplasms (MPNs) like myelofibrosis (MF), according to a new study published in ...